There is a large body of evidence that biological aging is related to a series of long-term catabolic processes resulting in decreased function and structural integrity of several physiological systems, among which is the cardiovascular system. These changes in the aging phenotype are correlated with a decline in the amplitude of pulsatile growth hormone secretion and the resulting decrease in plasma levels of its anabolic mediator, insulin like growth factor-1 (IGF-1). The relationship between growth hormone and biological aging is supported by studies demonstrating that growth hormone administration to old animals and humans raises plasma IGF-1 and results in increases in skeletal muscle and lean body mass, a decrease in adiposity, increased immune function, improvements in learning and memory, and increases in cardiovascular function. Since growth hormone and IGF-1 exert potent effects on the heart and vasculature, the relationship between age-related changes in cardiovascular function and the decline in growth hormone levels with age have become of interest. Among the age-related changes in the cardiovascular system are decreases in myocyte number, accumulation of fibrosis and collagen, decreases in stress-induced cardiac function through deterioration of the myocardial conduction system and b-adrenergic receptor function, decreases in exercise capacity, vessel rarefaction, decreased arterial compliance and endothelial dysfunction leading to alterations in blood flow. Growth hormone has been found to exert potent effects on cardiovascular function in young animals and reverses many of the deficits in cardiovascular function in aged animals and humans. Nevertheless, it has been difficult to separate the effects of growth hormone deficiency from age-related diseases and associated pathologies. The development of novel animal models and additional research are required in order to elucidate the specific effects of growth hormone deficiency and assess its contribution to cardiovascular impairments and biological aging.
Introduction
anabolic hormones including estrogen, androgen and numerous peptidergic trophic factors or hormones. Growth Biological aging can be physiologically characterized as hormone is one such hormone which has been characterthe interaction of various catabolic processes affecting ized as an important regulator of postnatal somatic growth. bone, muscle, brain, and cardiovascular structure and Growth hormone pulse amplitude declines with age due to function. One potential explanation for the increase in alterations in the normal dynamic interactions of two catabolism with age is a decline in plasma levels of hypothalamic hormones, somatostatin and growth hormone-releasing hormone. Generally, both adult-onset growth hormone deficiency and aging are manifest as a *Corresponding author. Tel.: 11-336-716-8605; fax: 11-336-716-decrease in lean body mass, increase in adiposity, decline 8501. in bone density, decreased skin thickness, decreased E-mail address: wsonntag@wfubmc.edu (W.E. Sonntag). 1 Center for Cell and Gene Therapy, Baylor College of Medicine, One Baylor Plaza, Texas Medical Center, Houston, TX 77030, USA.
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immune function, decline in learning and memory, and concentrations and acts as a mitogen, stimulating DNA, impaired myocardial function. Growth hormone replace-RNA and protein synthesis [13] . Although most of the ment reverses many of these changes; however, the effects circulating IGF-1 is derived from liver, growth hormone of growth hormone and its anabolic mediator, insulin-like may also have a role in regulating the synthesis and growth factor-1 (IGF-1), on the cardiovascular system are secretion of IGF-1 from many tissues, thereby directly complex and influenced by both age and disease. In this influencing the paracrine or local activities of the hormone review, we detail the current knowledge of the regulation [14] [15] [16] [17] . of growth hormone and its anabolic mediator, IGF-1. The IGF-1 circulates in blood either free (t is about 15-20 1 / 2 alterations in this system with age are described and the min) or bound to specific binding proteins that prolong the implication for the regulation of cardiovascular function in half-life of the peptide. Presently, six IGF-1 binding aged animals discussed.
proteins (IGFBPs) have been identified and constitute an elaborate system for regulating IGF-1 activity. IGFBPs function to regulate the availability of IGF-1 to its receptor 2. Growth hormone and aging in target tissues [18] , and specific proteases are required to cleave the IGF-1 protein from its binding protein complex.
General characteristics of growth hormone
Once IGF-1 binds to the type 1 IGF receptor, it initiates autophosphorylation of the receptor, IRS-1 (insulin rePure bovine growth hormone is a single chain polyceptor substrate) phosphorylation, and tyrosine phosphorylpeptide of 191 amino acids first isolated from the pituitary ation. Subsequent activation of Ras / Raf, PI 3-kinase and gland by Li et al. [1] . It was subsequently shown to MAP kinase results from IGF receptor activation [17] . stimulate fatty acid mobilization, amino acid uptake, DNA,
Although it was initially proposed that all of the actions of RNA and protein synthesis, thus regulating cell division growth hormone were mediated through IGF-1, several and tissue hypertrophy. In humans, growth hormone is studies have provided evidence that growth hormone has released in pulsatile bursts from the pituitary gland with direct effects on specific tissues and / or synergizes with the majority of secretion occurring nocturnally in associa-IGF-1 [19, 20] . tion with slow-wave sleep [2] [3] [4] [5] . Similar pulses are observed in rodents, except that high-amplitude secretory 2.2. Age-related changes in growth hormone and IGF-1 pulses occur every 3.5 h in males [6] and hourly in females. Although the precise function of this ultradian Initial studies in elderly humans designed to investigate pattern remains unknown, the pulsatile nature of growth the relationship between growth hormone and physiologihormone release has been confirmed in every species cal changes associated with age reported a decline in the examined to date and appears to be essential to optimize ability of individuals to secrete growth hormone in rebiological potency of the hormone. The regulation of these sponse to several stimuli, including insulin-induced hypopulses involve at least two hormones released by the glycemia and arginine administration [21] . Subsequent hypothalamus; growth hormone-releasing hormone studies revealed a loss of nocturnal surges of growth (GHRH) which increases growth hormone release [7, 8] hormone [22] and a decrease in plasma IGF-1 that and somatostatin which inhibits its release [9] . The dyparalleled the decline in growth hormone pulses [23, 24] . namic interactions between these hormones are responsible These early studies in humans have been confirmed by for high amplitude, pulsatile growth hormone secretion. It numerous investigators (see review by Corpas et al. [3] ) is generally believed that somatostatin tone is dominant and it is now evident that the decline in high-amplitude during trough periods, whereas when somatostatin is growth hormone secretion and plasma IGF-1 concentrasuppressed, growth hormone is released in response to tions is one of the most robust and well characterized secretion of GHRH [10] . endocrine events that occur with age. Once growth hormone is secreted from the anterior Shortly after the documentation of decreases in growth pituitary, it binds with high affinity to the growth hormone hormone secretion in aged humans, studies confirmed that receptor which is found in tissues throughout the body.
the amplitude of growth hormone pulses also decreased Plasma growth hormone is carried by a binding protein with age in rodents [25] (see Fig. 1 ) and that these which is homologous to the cleaved extracellular domain decreases were associated with a decline in plasma IGF-1 of the growth hormone receptor [11] . The growth hormone [26] . These studies immediately progressed to an invesmolecule exhibits two binding sites for the growth hortigation of the mechanisms responsible for the decline in mone receptor resulting in dimerization of the receptor, a growth hormone secretion. Several studies in both humans step that is required for biological activity of the hormone and animals documented a decreased in vivo pituitary [12] . Activation of the growth hormone receptor stimulates response to GHRH with age [27] [28] [29] . However, over the the synthesis and secretion of insulin-like growth factor-1 next several years, numerous studies attempting to detail (IGF-1), a small peptide (about 7.5 kD) structurally related the deficits within the pituitary gland produced controto proinsulin. IGF-1 circulates in the blood at high versial results which ultimately were attributed to either Fig. 1 . Representative plasma growth hormone concentration in young (6 months) and old (24 months) male rats. Each point represents the plasma growth hormone (ng / ml) at a specific time point in a conscious, freely moving young or old animal (adapted from Sonntag et al. [25] with permission).
differential responses of older animals to the pharmacorelease of GHRH, a decline in this hormone is another logical agents used to suppress endogenous growth horcontributing factor in the decrease in growth hormone mone pulses during in vivo testing [30] or to technical secretion with age. GHRH mRNA decreases with age [36] limitations involved with culturing anterior pituitary cells and the feedback relationship between growth hormone from older animals [31] .
and hypothalamic neurons is impaired [37] . In the latter study, growth hormone increased somatostatin mRNA and 2.3. Hypothalamic hormone regulation decreased GHRH mRNA in young animals, but in older animals GHRH neurons were non-responsive. As a result, Research efforts were eventually directed to an analysis it was concluded that deficiencies within the hypothalamus of hypothalamic releasing and inhibiting hormones after involving regulation of both GHRH and somatostatin are studies revealed that: (1) acute, in vivo, administration of responsible for the decrease in growth hormone secretion somatostatin antiserum increased growth hormone release with age. identically in both young and old animals [32], (2) passive immunization with somatostatin antiserum restored the in vivo deficiency in pituitary response to GHRH [30] , and 2.4. Tissue responsiveness to growth hormone (3) stimulation of hypothalamic slices of old animals in a superfusion system released greater amounts of somatoAlthough a decline in the amplitude of growth hormone statin than in those of young animals [33] . Our laboratory pulses is an important determinant of the decrease in has found that older animals release increased amounts of plasma IGF-1, more recent studies demonstrate that growth somatostatin peptide from pituitary extracts, suggesting an hormone induced IGF-1 secretion is diminished in elderly age-related increase in the release of this peptide from individuals and suggest that resistance to the action of hypothalamic neurons [34] . These results provided comgrowth hormone may be a secondary contributing factor in pelling evidence that increased somatostatin tone may be the low plasma IGF-1 concentrations [38] . In rodents, a an important factor in the decline in growth hormone two-fold increase in growth hormone receptors has been pulses with age. These conclusions were supported by observed with age but this increase fails to compensate for research demonstrating that administration of cholinergic the reduction in growth hormone secretion [39, 40] . A more agonists or arginine, considered to preferentially inhibit detailed investigation revealed that the K and apparent D somatostatin release, was capable of restoring growth size of the growth hormone receptor were not altered with hormone secretion in the elderly [34, 35] .
age [W.E. Sonntag, unpublished observations] whereas the Although these studies did not address the synthesis and capacity of growth hormone to induce IGF-1 gene expres-sion and secretion was 40-50% less in old than in young growth hormone and that these decreases were accomanimals.
panied by a decline in MAP kinase activity. More recent The activated growth hormone receptor associates with studies demonstrate that growth hormone induced STAT3 JAK2 with subsequent phosphorylation of both proteins activation and nuclear translocation are also decreased with [41] (see review by Roupas and Herington [42] ) (Fig. 2) .
age [46] . Although these studies did not address the Several other intracellular proteins are subsequently phosetiology of the decrease in JAK2 activity, they established phorylated, including mitogen-activated protein kinase that diminished growth hormone receptor signal transduc-(MAP kinase), S6 kinase and the STAT proteins (signal tion is a contributing factor in the decrease in IGF-1 transducer and activator of transcription). The result is an expression with age. increase in c-fos, c-jun, serine phosphatase inhibitor-1 and IGF-1 gene expression [43] . Although diminished signal transduction has been described for both the insulin and 3. Effects of growth hormone on the cardiovascular IGF-1 receptors in aged animals [44, 45] , studies have not system addressed alterations in growth hormone receptor signaling. Xu et al. [40] subsequently reported that phos-3.1. Preclinical studies phorylation of JAK2 and the growth hormone receptor complex were suppressed in aged rodents in response to
The concept that growth hormone has effects on the cardiovascular system and may reverse age-related changes be avoided by utilizing either bovine or porcine growth in cardiovascular function is based on both in vivo and in hormone which exhibit higher sequence homology to rat vitro studies. Cardiac myocytes contain receptors for growth hormone. Finally, the high pharmacological doses growth hormone [47] [48] [49] and cultured myocytes are of growth hormone used in these studies may cause responsive to growth hormone administration [49] . Growth acromegalic-like side effects, insulin resistance, and an hormone has been shown to regulate cardiac growth in increased risk of pathogenesis with long term use. vivo (including myocyte growth) [50] . Growth hormone Despite these limitations, administration of growth has also been demonstrated to increase LV pump function, hormone to rats in physiological doses has been demonand has favorable effects on LV remodeling and contractile strated to ameliorate many age-related changes in the processes in pigs with congestive heart failure (CHF) [51] . cardiovascular system. First, the age-related rarefaction of Two studies have suggested that stimulation of the IGF-1 both brain [54] and myocardial vessels [55] was partially receptor results in phosphorylation of the b-adrenergic reversed by administration of bovine growth hormone. It is receptor [52, 53] and may partially reverse the age-related of interest that in this latter study the effects of growth decline in b-adrenergic activity. Therefore, it is likely that hormone on microvascular density were limited to specific growth hormone, either directly or through IGF-1, has regions of the heart and it was suggested that the actions of potent effects on the heart and has the capacity to improve growth hormone may be limited by fibrosis which was myocardial function in aged animals or in response to prevalent in the aged animals. Growth hormone adminisspecific diseases that affect the cardiovascular system. tration to aged rats also increased coronary blood flow (see Although these studies provide evidence for a role of . These results suggest that lower, physiological the conclusions are often based on the use of high doses of doses of growth hormone are able to reverse some of the human growth hormone in rodents that introduce several changes in cardiovascular structure and function with age potentially confounding variables. Human growth hormone and raise the concept that age-related decreases in growth is both antigenic and prolactinogenic which can potentially hormone have the potential to contribute to impairments in limit anabolic effects and introduce non-specific actions of cardiovascular function observed in aged animals. the hormone. For rodent models, these two problems can Several investigators have examined the differential and saturating Ca concentration declined between young Brown Norway rats treated with saline (8 months, YSAL) and old animals treated with saline (8 months, OSAL), and was significantly restored in old animals treated with growth hormone (28 months, OGH) (from Wannenburg et al. [56] with permission). synergistic cardiac effects of growth hormone and IGF-1.
hormone on the heart are mediated through IGF-1 and that Cittadini et al.
[57] administered recombinant human both hormones exert independent and interacting effects on growth hormone, recombinant human IGF-1, and a combicardiac structure and function. However, a limitation of nation of both hormones to 3-month-old Sprague-Dawley these studies is that the differential effects of growth rats. Echocardiography revealed that combination therapy hormone and IGF-1 could be due to physiological differwith growth hormone and IGF-1 did not have synergistic ences in the doses of hormones. While it is established that effects on myocardial growth or function. However, cargrowth hormone and IGF-1 affect cardiac structure and diac output and stroke volume were increased in response function, further studies are required to determine the to IGF-1 and / or in response to the combination of growth specific dose of growth hormone necessary to improve hormone and IGF-1 compared to controls and growth cardiovascular function while minimizing pathological hormone treated animals. Another study examined the in effects. vitro effects of growth hormone and IGF-1 on intracellular calcium [58] . No acute effects of growth hormone were 3.2. Growth hormone therapy in animal models of found on cardiac function, although IGF-1 caused an congestive heart failure increase in isovolumic developed pressure without a 21 change in intracellular [Ca ] . Further studies of isolated Growth hormone administration has been considered as ferret papillary muscles demonstrated that the effects of a possible treatment for heart failure [60] and has been IGF-1 on contractility could be blocked by wortmannin, an shown to improve left ventricular contractility in rats with inhibitor of PI-3 (phosphatidylinositol-3 kinase), an inexperimental heart failure and cardiomyopathy. In an tracellular kinase stimulated by IGF-1 receptor activation experimental model of heart failure, involving left cor-[59]. These results suggest that IGF-1 is able to increase onary artery ligation [61] , growth hormone administration contractility in vitro by altering myofilament calcium increased stroke volume and decreased mean arterial sensitivity, not through increasing intracellular calcium.
pressure through a decrease in systemic vascular resistStudies utilizing combination therapy with growth horance. LV contractility, as measured by LV dP/dt, was also mone and IGF-1 suggest that some of the effects of growth improved by growth hormone. Except for an increase in body weight and decrease in mean arterial pressure, growth mone plasma levels and ejection fraction was demonstrated hormone administration did not have a significant effect in in twelve patients with cardiomyopathy [68] . In a single control animals. This study suggests that improvements in case report of a patient with hypopituitarism, dilated LV contractility, mean arterial pressure, and stroke volume cardiomyopathy was partially reversible with growth horoccur with administration of growth hormone in animals mone administration [60] and growth hormone withdrawal with experimental heart failure.
resulted in recurrent thinning of the myocardial wall and a A recent study by Ryoke et al. [62] examined the effects decrease in LV ejection fraction. Although this is a single of growth hormone administration on LV dysfunction in report of a patient experiencing Sheehan's syndrome cardiomyopathic hamsters. This strain becomes car-(postpartum hypopituitarism) and both cortisol and thyroxdiomyopathic due to an autosomal recessive mutation of ine were also involved in the 3-month hormone replacethe gene for D-sarcoglycan, part of the dystrophin complex ment therapy, the findings suggest that the cardiomyopathy [63, 64] . LV contractility improved with growth hormone associated with Sheehan's syndrome may be due, in part, treatment but to a greater degree in the younger versus to growth hormone deficiency. older animals. LV wall stress at end systole was reduced by Genth-Zotz et al.
[69] demonstrated that growth horgrowth hormone administration in 4-month-old animals mone replacement improved cardiac function in patients whereas wall stress increased at end diastole in response to with ischemic cardiomyopathy. Interestingly, growth horgrowth hormone in 10-month-old animals. It was therefore mone was administered at a relatively low dose-half the concluded that growth hormone administration has benefidose shown to be effective in growth hormone deficient cial effects on LV contractility and wall stress but the cardiomyocytes [60] . In this study, exercise capacity, response is blunted with age.
cardiac output, myocardial wall thickness increased while Tajima et al. [65] recently proposed a possible mechaend systolic and diastolic volume indices decreased. Hownism whereby growth hormone can increase myocardial ever, there was no increase in LV ejection fraction. The contractility and contractile reserve. This group showed effects were maintained for 3 months and began to that 14 days of growth hormone treatment to rats with diminish after withdrawal of growth hormone therapy. It is postinfarction heart failure improved cardiac function.
unknown whether these effects were mediated by increased Contractile reserve was depressed in rats after experimen-IGF-1 levels or changes in myocardial structure. In conclutal myocardial infarction, as would be expected. However, sion, growth hormone administration is beneficial to growth hormone treatment restored myocyte contractility cardiomyopathic humans and individuals with adult-onset and this effect was correlated with increases in SERCA-2 growth hormone deficiency.
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(sarcoplasmic reticulum Ca ATPase-2) mRNA and protein in the left ventricle. This suggests that growth hormone can restore contractility by modulating synthesis 4. Animal models of growth hormone deficiency of proteins involved in excitation-contraction coupling.
The complexities of studying the interactions of growth 3.3. Clinical studies of growth hormone in congestive hormone with disease processes in humans have raised heart failure questions concerning the precise role(s) of growth hormone deficiency and replacement in normal cardiovascular funcGrowth hormone / IGF-1 deficiency has been implicated tion. However, it has been difficult to separate the direct as a potential cause of decreases in cardiac mass and effects (or absence of effects) of growth hormone in aged ventricular wall thickness in humans. Amato et al. [66] animals and humans from numerous pathologies that occur demonstrated that administration of recombinant human with age. Despite the studies implicating alterations in growth hormone to growth hormone deficient adults growth hormone and IGF-1 in the process of biological increased left ventricular wall thickness and mass. Another aging, a model to mimic age-related changes in these double-blind study utilized long term administration of hormones has been elusive and further progress in the field growth hormone to adult-onset growth hormone deficient requires the development of a proper animal model to humans and demonstrated improved exercise performance distinguish the effects of growth hormone deficiency from and cardiac output [67] . Doppler-echo techniques used in the effects of aging. this study revealed that patients administered growth
Over the past decade, several animal models of growth hormone had an increased LV mass index and intervenhormone deficiency (or excess) have been developed [70] tricular septum size as well as improved exercise perbut the interpretation of these studies are limited since the formance. This study suggested that long-term growth alterations in growth hormone do not resemble changes hormone replacement therapy is generally well-tolerated found in the aging human or the animals exhibit other and increases LV mass index and stroke volume.
endocrine deficiencies that confound the interpretation of Studies in humans have also suggested that growth the data. For example, transgenic animals with high hormone deficiency can result in cardiomyopathy. A (supraphysiologic) levels of growth hormone exhibit abpositive correlation between mean nocturnal growth hornormal growth in a number of tissues (similar to acromega-ly in humans) and develop early pathological changes in col in order to separate growth hormone deficiency from tissues which limit lifespan. On the contrary, many of the other endocrine anomalies. Specifically, the pancreas in studies conducted in dwarf rodents (Ames and Snell dwarf dwarf rats appears underdeveloped and does not secrete animals) as well as the recently developed growth hormone adequate insulin compared to control rats when challenged receptor knockout mouse are of limited use as a model of during a glucose tolerance test. However, dwarf animals growth hormone deficiency for aging studies since (1) administered growth hormone for 10 weeks appear to have there are alterations in numerous endocrine systems restored pancreatic function. Growth hormone replacement besides growth hormone and IGF-1, (2) developmental also increases body weight and plasma IGF-1 to levels differences exist due to the absence of these hormones found in heterozygous controls. The dw / dw model is during critical phases of growth and introduce non-specific currently being used to assess the effects of adult onset differences between the dwarf and wild-type animals, and growth hormone deficiency by comparing dwarfs treated (3) there are significant decreases in body size. Ames and withdrawn from growth hormone therapy to dwarfs dwarf mice, for example, lack pituitary cells that produce that are continuously treated with growth hormone. This growth hormone, prolactin and thyroid stimulating horanimal model appears to resolve many of the issues related mone due to a mutation of the Prophet of pit-1 (prop-1)
to the developmental effects of growth hormone deficiency gene [70] . These primary multiple endocrine deficiencies, and will undoubtedly be useful in advancing our undersecondary endocrine anomalies (e.g. excess cortisol and standing of the consequences of growth hormone deimpaired insulin secretion) and issues related to developficiency on the aged cardiovascular system. ment limit the interpretation of data from this model since it would not be evident whether the resulting effects were directly related to growth hormone deficiency.
Conclusions
More recent models have used the dw / dw rat that exhibits an unknown mutation in the growth hormone
The hypothesis that a decline in growth hormone and secretory axis resulting in dwarfism. The hormonal de-IGF-1 has an important role in mechanisms of aging has ficiency is isolated to growth hormone with levels about gained substantial support in recent years since it has been 10% of normal while plasma IGF-1 declines to 50% of demonstrated that administration of these hormones to levels found in heterozygote littermates. Analysis also aged animals restores cellular protein synthesis [74] and indicates that these animals have no changes in basal increases lean body mass [75] , immune function [76, 77] , glucose, insulin, glucocorticoids or T / T . Cittadini et al.
skin thickness [78] and vertebral bone density [75, 79, 80] . 3 4 [71] have recently published studies examining various Furthermore, the age-related decrease in these hormones parameters of myocardial structure and function in this also appears to be involved in the decline in cardiovascular model. One study investigated postinfarction healing in function with age since the results of several studies dwarf rats versus controls and found that LV dilation and suggest that growth hormone replacement can improve or dysfunction are exaggerated in dwarf animals [71] . Two reverse many of these deficits. Recent studies from our subsequent studies examined the effects of growth horlaboratory demonstrate that low doses of growth hormone mone deficiency and human growth hormone administrahave beneficial effects on myocardial structure and function on cardiac morphology and function. Using echtion in aged animals, e.g. increasing coronary flow, capilocardiography, Longobardi et al. [72] were able to demonlary density, and myofilament contractility. However, the strate an improvement in cardiac output and increase in effects of growth hormone and IGF-1 deficiency may not myocyte area with growth hormone administration.
be fully recognized since aged animals are compromised Another study reported a decrease in maximal calcium by pathological changes and current, alternative animal activated force and b-adrenergic responsiveness as meamodels of growth hormone deficiency have been comprosured in an LV papillary muscle preparation, and a mised by multiple endocrine deficiencies. The developsubsequent increase in myocyte area, developed tension ment of new models of growth hormone deficiency that are per cross-sectional area and maximal calcium activated specific to growth hormone will advance our understanding force [73] . While limited due to the antigenic and prolacof the role of growth hormone in the maintenance of tissue togenic effects of human growth hormone, these were the function and in aging. first reports of deficits in cardiovascular structure and Despite the evidence that growth hormone administrafunction in growth hormone deficient animals. Furthertion may be beneficial to the cardiovascular system, these more, these studies suggest that growth hormone replaceresults must be balanced with possible side effects of ment can reverse many of the deficits seen in cardiovascugrowth hormone replacement. Growth hormone is potenlar function in growth hormone deficient rats.
tially diabetogenic and recent studies have established Recent studies in our laboratory have provided addition-IGF-1 as a risk factor for lung, breast, prostate and al information related to the utility of this animal model. colorectal cancer [81] . These issues indicate that further Our results indicate that the dwarf animal has pancreatic studies are essential to overcome the concerns of treating insufficiencies which may require a modification in protonormal aging humans with growth hormone. More re- 
